患有炎症性肠病的人更喜欢用于疲劳管理的认知行为疗法:联合分析
Catherine Emerson1, David Skvarc2,3, Antonina Mikocka-Walus2,4
1School of Psychology, Deakin University Geelong, 221 Burwood Highway Burwood 3125, Geelong, VIC, Australia. catherine.emerson@deakin.edu.au.
Digestive diseases and sciences
|May 11, 2024
概括
患有炎症性肠病 (IBD) 的患者更喜欢在线认知行为疗法 (CBT) 来管理疲劳. 这种简短的在线CBT干预比其他心理方法更受青.
科学领域:
- 胃肠病学 胃肠病学
- 心理学 心理学 心理学
- 患者为中心的护理
背景情况:
- 疲劳是患有炎症性肠病 (IBD) 的患者的一个重要问题.
- 心理干预表明IBD疲劳管理的承诺.
- 以前的干预措施缺乏患者对首选干预类型的实质性投入.
研究的目的:
- 探索患者对针对IBD疲劳的心理干预措施的偏好.
- 确定患者在疲劳管理计划中所重视的关键属性.
主要方法:
- 一项国际在线横截面调查对自我报告的IBD的成年人进行了管理.
- 使用联合分析来评估对干预类型,交付方式和持续时间的偏好.
- 834名IBD患者参与了这项研究.
主要成果:
- 心理干预的类型是患者偏好的最关键因素.
- 认知行为疗法 (CBT) 是最喜欢的干预类型.
- 患者更喜欢短暂的在线交付方式来进行疲劳管理干预.
结论:
- 这些发现为开发以患者为中心的IBD心理疲劳干预措施提供了明确的方向.
- 治疗师和程序开发人员可以利用这些偏好来增强程序设计.
- 简短的在线CBT干预是IBD患者强烈喜欢的疲劳管理.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Irritable Bowel Syndrome III: Medical and Nursing Management
196
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
196
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Drugs for Treatment of Constipation-Predominant IBS
160
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
160
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131


